Teva Pharmaceutical Industries
TEVA
39.23
+0.69
+1.79%
Teva Pharmaceutical Industries
US · TEVA
#471 by market cap
Listed 1970
39.23
+0.69
+1.79%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q4).
- Total institutional ownership fell 1.4 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 79.39% -1.37pp
- Institutions
- 782 -1
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund52.46%
Public Company11.21%
Sovereign Wealth Fund6.06%
Hedge Fund4.47%
Private Company1.66%
Government Pension Fund1.62%
Family Office/Trust1.57%
Individual/Insider0.41%
Insurance Company0.18%
Other20.35%
Top holders as of 2026-09-30
Harel Insurance Investments & Financial Services Ltd
8.92% · 104.05M sh
Norges Bank Investment Management
6.01% · 70.08M sh
BlackRock
5.44% · 63.42M sh
Phoenix Investments & Finances Ltd
4.85% · 56.55M sh
Menora Mivtachim Provident Funds
4.48% · 52.28M sh
Vanguard Capital Management, LLC
3.68% · 42.97M sh
WCM Investment Management
3.62% · 42.25M sh
Clal Financial Management Ltd
3.61% · 42.09M sh
Migdal Mutual Funds Ltd.
3.50% · 40.87M sh
FMR
1.90% · 22.17M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 23 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Amir Elstein | Independent Director | 0.18% |
| Richard Francis | Chief Executive Officer | 0.08% |
| Sol Barer | Independent Chairperson | 0.04% |
| Eric Hughes | Former Executive VP of Global R&D and Chief Medical Officer | 0.01% |
| Gerald Lieberman | Independent Director | 0.01% |
| Rosemary Crane | Independent Director | 0.01% |
| Roberto Mignone | Independent Director | 0.01% |
| Perry Nisen | Independent Director | 0.01% |
| Ronit Satchi-Fainaro | Independent Director | 0.01% |
| Mark Sabag | Executive Vice President of International Markets Commercial | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-11 | Mark Sabag | Executive Vice President of International Markets Commercial | Derivative Exercise and Sale | -44,710 | $34.90–44.14 |
| 2026-11-10 | Richard Daniell | Executive Vice President of European Commercial | Derivative Exercise and Sale | -45,003 | $34.70–42.91 |
| 2026-11-10 | Richard Daniell | Executive Vice President of European Commercial | Intent to Sell (Form 144) | -20,003 | $42.80 |
| 2026-11-09 | David Brailer | Independent Director | Other Derivative Acquisition | +3,326 | -- |
| 2026-11-09 | Richard Francis | Chief Executive Officer | Automatic Disposition | -250,000 | $42.24 |
| 2026-11-09 | Dov Bergwerk | Senior VP & Company Secretary | Other Derivative Acquisition | +9,433 | -- |
| 2026-11-08 | Richard Daniell | Executive Vice President of European Commercial | Intent to Sell (Form 144) | -25,000 | $42.91 |
| 2026-11-08 | Amir Weiss | Chief Accounting Officer | Open Market Disposition | -9,534 | $43.03 |
| 2026-11-08 | Amir Weiss | Chief Accounting Officer | Derivative Exercise and Sale | -7,755 | $34.70–43.15 |
| 2026-11-04 | Mark Sabag | Executive Vice President of International Markets Commercial | Derivative Exercise and Sale | -46,000 | $34.90–41.93 |
| 2026-11-03 | Dov Bergwerk | Senior VP & Company Secretary | Derivative Exercise and Sale | -26,260 | $28.98–41.72 |
| 2026-09-28 | Dov Bergwerk | Senior VP & Company Secretary | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Bridger Management LLC | -- | Intent to Sell (Form 144) | -367,600 | $39.19 |
| 2026-09-17 | Brian Savage | Interim Chief Legal Officer | Open Market Disposition | -2,839 | $38.70–39.15 |
| 2026-09-17 | Brian Savage | Interim Chief Legal Officer | Derivative Exercise and Sale | -4,503 | $34.70–38.69 |
| 2026-08-20 | Ronit Satchi-Fainaro | Independent Director | Private Disposition | -415 | $37.25 |
| 2026-08-20 | Amir Weiss | Chief Accounting Officer | Private Disposition | -6,945 | $37.61 |
| 2026-08-20 | Amir Weiss | Chief Accounting Officer | Derivative Exercise and Sale | -2,500 | $19.61–37.63 |
| 2026-08-16 | Evan Lippman | Officer | Automatic Disposition | -18,600 | $36.57 |
| 2026-08-04 | Tal Zaks | Independent Director | Private Disposition | -17 | $34.87 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:26 · For reference only, not investment advice and not tailored to your situation.
Teva Pharmaceutical Industries discussion 0 comments